Log In Sign up
The largest database of trusted experimental protocols

Apoe 139 152

Manufactured by Cell Biolabs
Visit Supplier

ApoE 139-152 is a synthetic peptide corresponding to amino acids 139-152 of the human apolipoprotein E (ApoE) protein sequence. It is commonly used as a research tool in cellular and biochemical studies.

Automatically generated - may contain errors

Lab products found in correlation

Anti apoe, by Merck Group (2 mentions) Recombinant apoe isoforms, by BioCat (2 mentions) Apoe3, by Romer Labs (2 mentions) Apoe 75 85, by Cell Biolabs (2 mentions) Apoe 210 232, by Cell Biolabs (2 mentions) Mda ldl, by Cell Biolabs (2 mentions) Copper oxidized ldl oxldl, by Thermo Fisher Scientific (2 mentions) Anti c5b 9 clone ae11, by Agilent Technologies (2 mentions) Anti aβ clone32a1, by AbFrontier (2 mentions)

2 protocols using apoe 139 152

1

Characterization of Complement-ApoE Interactions

Check if the same lab product or an alternative is used in the 5 most similar protocols
Complement components C2, C3, C3b, C4, C4b, C1q, C1s, Factor H, Factor
I, and C4BP as well as all primary antibodies (anti C1q, A200/3b; anti C2,
A212/18b; anti C3, A213/5a; anti C4, A201/3a; anti factor H, A237/4) were
purchased from Complement Technology. Recombinant ApoE isoforms from BioCat;
plasma-purified ApoE3 from Biopure. ApoE peptides were generated by Peptide 2.0:
ApoE 30-40 LGRFWDYLRWV; ApoE 75-85 YKSELEEQLTPV; ApoE 139-152 SHLRKLRKRLLRDA;
ApoE 210-232 WGERLRARMEEMGSRTRDRLDEV. LDL and malondialdehyde-modified LDL
(MDA-LDL) were from Cell Biolabs, copper oxidized LDL (oxLDL) from Thermo Fisher
(L34357), ApoA from Athens Research&Technology, vitronectin (Vnt) from
Corning. Aβ and Aβ fibrils from GenSript. Recombinant EfB was
expressed as described65 . Additional
antisera used were: anti-C5b-9 (clone AE11-MO777-Dako), anti C1s
(11951-05011-AssaybioTch), anti ApoE ((178479-Calbiochem), anti ApoE (Merck,
178479), anti LDLR (HB04JL2204-B-SinoBiological), anti Aβ (clone
32A1-Abfrontier), anti goat IgG (13C0836-Sigma Aldrich) and anti rabbit IgG
(13C0529-Sima Aldrich), IgM (120228-Jackson ImmunoResearch Laboratories).
Yin C., Ackermann S., Ma Z., Mohanta S.K., Zhang C., Li Y., Nietzsche S., Westermann M., Peng L., Hu D., Bontha S.V., Srikakulapu P., Beer M., Megens R.T., Steffens S., Hildner M., Halder L.D., Eckstein H.H., Pelisek J., Herms J., Roeber S., Arzberger T., Borodovsky A., Habenicht L., Binder C.J., Weber C., Zipfel P.F., Skerka C, & Habenicht A.J. (2019). ApoE attenuates unresolvable inflammation by complex formation with activated C1q. Nature medicine, 25(3), 496-506.
+ Open protocol
+ Expand
2

Characterization of Complement-ApoE Interactions

Check if the same lab product or an alternative is used in the 5 most similar protocols
Complement components C2, C3, C3b, C4, C4b, C1q, C1s, Factor H, Factor
I, and C4BP as well as all primary antibodies (anti C1q, A200/3b; anti C2,
A212/18b; anti C3, A213/5a; anti C4, A201/3a; anti factor H, A237/4) were
purchased from Complement Technology. Recombinant ApoE isoforms from BioCat;
plasma-purified ApoE3 from Biopure. ApoE peptides were generated by Peptide 2.0:
ApoE 30-40 LGRFWDYLRWV; ApoE 75-85 YKSELEEQLTPV; ApoE 139-152 SHLRKLRKRLLRDA;
ApoE 210-232 WGERLRARMEEMGSRTRDRLDEV. LDL and malondialdehyde-modified LDL
(MDA-LDL) were from Cell Biolabs, copper oxidized LDL (oxLDL) from Thermo Fisher
(L34357), ApoA from Athens Research&Technology, vitronectin (Vnt) from
Corning. Aβ and Aβ fibrils from GenSript. Recombinant EfB was
expressed as described65 . Additional
antisera used were: anti-C5b-9 (clone AE11-MO777-Dako), anti C1s
(11951-05011-AssaybioTch), anti ApoE ((178479-Calbiochem), anti ApoE (Merck,
178479), anti LDLR (HB04JL2204-B-SinoBiological), anti Aβ (clone
32A1-Abfrontier), anti goat IgG (13C0836-Sigma Aldrich) and anti rabbit IgG
(13C0529-Sima Aldrich), IgM (120228-Jackson ImmunoResearch Laboratories).
Yin C., Ackermann S., Ma Z., Mohanta S.K., Zhang C., Li Y., Nietzsche S., Westermann M., Peng L., Hu D., Bontha S.V., Srikakulapu P., Beer M., Megens R.T., Steffens S., Hildner M., Halder L.D., Eckstein H.H., Pelisek J., Herms J., Roeber S., Arzberger T., Borodovsky A., Habenicht L., Binder C.J., Weber C., Zipfel P.F., Skerka C, & Habenicht A.J. (2019). ApoE attenuates unresolvable inflammation by complex formation with activated C1q. Nature medicine, 25(3), 496-506.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!